Welcome to our dedicated page for KalVista Pharmaceuticals SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KalVista Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KalVista Pharmaceuticals's regulatory disclosures and financial reporting.
KalVista Pharmaceuticals, Inc. chief medical officer Paul K. Audhya reported the disposition of his equity awards in connection with the company’s merger into a subsidiary of Chiesi Farmaceutici S.p.A. On June 11, 2026, his holdings in 150,260 shares of common stock were cancelled.
The filing shows additional dispositions of restricted stock units covering 93,750, 68,750, and 40,000 shares of common stock, as well as stock options over 25,800 shares at $9.28 and 100,000 shares at $24.97 per share. According to the merger agreement, in-the-money options and RSUs became fully vested and were converted into cash based on the $27.00 per-share merger consideration, while options with exercise prices at or above $27.00 were cancelled without payment. Following these transactions, the report shows no remaining holdings for the reporting person.
KalVista Pharmaceuticals director Bethany Sensenig reported the disposition of stock options as part of the company’s merger with Chiesi Farmaceutici. A total of 45,000 options with a per share exercise price of $12.05 were cancelled and converted into a cash right based on the merger consideration of $27.00 per share. Following the transaction, no options from this grant remain outstanding.
KalVista Pharmaceuticals director Patrick Treanor reported the disposition of several stock option grants to the issuer in connection with KalVista’s cash merger with Chiesi Farmaceutici. Under the merger, all KalVista common shares were acquired for $27.00 per share, and his fully vested in-the-money options were cancelled and converted into cash rights based on the spread between this merger price and each option’s exercise price.
KalVista Pharmaceuticals, Inc. Chief Commercial Officer Nicole Sweeny reported the disposition of her equity in connection with the company’s merger into a subsidiary of Chiesi Farmaceutici. On June 11, 2026, she disposed of 59,291 shares of common stock and cancelled multiple restricted stock unit (RSU) awards and stock options back to the issuer.
Under the merger agreement, all outstanding KalVista common shares were acquired via a cash tender offer at $27.00 per share, and unexercised options and RSUs were cancelled in exchange for cash based on this consideration, or cancelled without payment if the option exercise price was at or above $27.00. Following these transactions, Sweeny reports zero shares and zero derivatives owned, reflecting the cash-out of her position as KalVista became a wholly owned subsidiary of Chiesi.
KalVista Pharmaceuticals' Chief Operations Officer, Arif Bilal, reported the cash-out of equity awards tied to the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, 49,000 restricted stock units and 100,000 stock options were disposed of to the issuer as part of a completed merger.
Under the Merger Agreement, Chiesi’s subsidiary acquired all outstanding KalVista common shares for $27.00 per share in cash, then merged with KalVista, which now operates as a wholly owned subsidiary. Unexercised options with an exercise price below the $27.00 merger consideration and outstanding RSUs were fully vested, cancelled, and converted into cash payments based on formulas set in the agreement, while underwater options were cancelled with no payment.
KalVista Pharmaceuticals director Reid Laurence reported the disposition of a stock option grant in connection with the company’s acquisition by Chiesi Farmaceutici. A stock option covering 17,000 shares of common stock with a per share exercise price of $10.07 was surrendered to the issuer.
Under the merger agreement, a Chiesi subsidiary completed a cash tender offer for all outstanding KalVista common shares at $27.00 per share, after which the subsidiary merged into KalVista on June 11, 2026, making KalVista a wholly owned subsidiary. Per the merger terms, in-the-money options such as this one became fully vested, were cancelled, and converted into the right to receive a cash payment based on the difference between the merger price and the option exercise price, multiplied by the number of option shares. Options with exercise prices at or above $27.00 were cancelled for no consideration.
KalVista Pharmaceuticals director Edward W. Unkart disposed of stock options in connection with the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, he surrendered a total of 109,000 stock options to the issuer in multiple transactions coded as dispositions to issuer.
According to the merger agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, after which the merger closed and KalVista became a wholly owned subsidiary. Each outstanding in-the-money option was cancelled and converted into a right to receive cash equal to the spread between the $27.00 consideration and its exercise price, multiplied by the number of underlying shares.
KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported the disposition of his equity in connection with the company’s merger with Chiesi Farmaceutici. A total of 479,989 shares of common stock and multiple restricted stock units and stock options were cancelled and converted into cash rights under the merger terms at a cash price of $27.00 per share for common stock or, for in-the-money options, the cash value of the spread. Following these transactions, the filing shows no remaining reported holdings for these securities.
KalVista Pharmaceuticals chief development officer Christopher Yea reported dispositions of all his equity in connection with the company’s merger with Chiesi Farmaceutici. A tender offer and subsequent merger converted issued and outstanding common shares into cash at $27.00 per share, subject to tax withholding. Yea disposed of 229,918 shares of common stock and multiple restricted stock unit and stock option awards, which were cancelled under the merger terms. Vested options with exercise prices below $27.00 were converted into cash payments based on the spread, while options at or above that price were cancelled without consideration, leaving him with no remaining reported holdings.
KalVista Pharmaceuticals’ Chief Financial Officer Brian Piekos disposed of his equity awards in connection with the company’s cash sale to Chiesi Farmaceutici. He returned 21,661 shares of common stock to the issuer and cancelled 93,750 and 55,000 share restricted stock unit awards.
Pursuant to the merger agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, after which the acquirer merged with KalVista. Outstanding stock options with exercise prices below the $27.00 merger consideration, including 100,000 options at $11.87 per share, and all RSUs became fully vested and were converted into rights to receive cash, leaving Piekos with no remaining reported holdings.